Business
Voyageur Signs Letter of Intent to Engage THINQ for Pharmaceutical Consulting, and Collaboration on Long Term Pharmaceutical Drug Development
(via TheNewswire) Calgary, Alberta - TheNewswire - July 27th, 2020...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Signs Letter of Intent to Engage THINQ for Pharmaceutical Consulting, and Collaboration on Long Term Pharmaceutical Drug Development(via TheNewswire)\n \n \nCalgary, Alberta - TheNewswire - July 27th, 2020 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the \"Company\" or \"Voyageur\") is pleased to announce the signing of a LOI with THINQ Pharma-CRO Ltd (http://www.THINQcro.com/index.html), a pharmaceutical drug development and manufacturing company based in India. The LOI will be followed with a formal contract to engage THINQ for services for global regulatory consulting and management, generic drug and natural health product development and formulations, supply of iodine contrast's active pharmaceutical ingredients; Iopamidol and iohexol to be used in Voyageurs' IoX product line. THINQ will manage third party barium and iodine contrast media manufacturing in India, including regulatory management of contrast media to the Indian regulatory authority. . \n\n\n \nThis new working agreement will allow Voyageur to commence near term cash flow revenues located in the Indian market. THINQ and Voyageur will also collaborate with the design of a large scale iodine production facility that will be tied into Voyageurs subterranean brine projects. This new collaboration will enable Voyageur to become fully integrated and achieve its Earth to the Bottle pharmaceutical strategy. THINQ has ownership of a unique proprietary technology for the creation of Iopamidol and Iohexol API manufacturing. This technology will be integral in moving the iodine contrast project forward. \n\n \n \nTHINQ is an integrated pharmaceutical Company having capabilities and capacities to develop and manufacture APIs , intermediates and advanced intermediates; development and manufacturing of natural products; development of generic formulations and has very strong network of manufacturers and suppliers in India and around the world for Contract manufacturing of finished formulations. THINQ has API manufacturing plant designed specifically for contrast media, have 3 USDMFs, 3 Approved CEPs over 5 submissions for API in pipeline . THINQ has a strong regulatory division which can handle compliance, manufacturing and supply for all geographies of the world. \n\n \n \nBrent Willis, CEO of Voyageur states \"We look forward to working with THINQ on moving our projec...